• Patient-Derived Gastric Cancer Assembloids Reveal Stromal Im

  2026-05-09

  This study establishes a novel patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations, better recapitulating tumor microenvironment complexity. The model demonstrates that stromal components can significantly alter gene expression and drug response, offering a robust platform for investigating tumor–stroma interactions and optimizing personalized therapies.

• Bile Acid Metabolism Subtypes Define Immune Markers in CRC

  2026-05-08

  Feng et al. (2026) present an integrative subtyping of colorectal cancer (CRC) based on bile acid metabolism, identifying CLCA1, UGT2A3, and ZG16 as key genes linked to immune dysfunction and prognosis. Their multi-cohort analysis clarifies the interplay between metabolic dysregulation, tumor immune microenvironment, and survival outcomes, offering new molecular targets for translational research.

• Tacalcitol Monohydrate: Applied Protocols in Cancer & Skin R

  2026-05-07

  Tacalcitol monohydrate, a synthetic analog of vitamin D3, empowers advanced experimental workflows across dermatology and oncology by precisely modulating VDR-dependent gene expression. Explore how APExBIO's high-purity Tacalcitol streamlines NGF induction, enhances 5-fluorouracil efficacy, and minimizes calcemic toxicity in demanding in vitro and translational studies.

• Deep Learning Reveals Cardiotoxicity in iPSC-CM Screening

  2026-05-07

  This study demonstrates the use of deep learning to detect drug-induced cardiotoxicity in high-throughput screens using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). The approach enables early identification of compounds with cardiac liabilities, offering practical advances for drug development and safety pharmacology.

• Advancing In Vitro Drug Response Metrics in Cancer Research

  2026-05-06

  Schwartz (2022) systematically distinguishes between proliferative arrest and cell death in anti-cancer drug screening, revealing that most compounds—including artemisinin derivatives—modulate both processes with varying kinetics. This improved framework for in vitro assessment provides oncology researchers with more nuanced and actionable data for preclinical evaluation.

• 5-Azacytidine: Mechanisms and Strategies for Translational E

  2026-05-06

  This thought-leadership article synthesizes recent mechanistic insights into 5-Azacytidine (5-AzaC) as a DNA demethylation agent with actionable guidance for translational researchers. Grounded in benchmark studies and enhanced by scenario-driven workflow recommendations, the piece critically distinguishes the translational promise of 5-Azacytidine from generic product literature. It further contextualizes APExBIO’s 5-Azacytidine within the evolving landscape of epigenetic oncology research, spotlighting unique experimental opportunities and strategic considerations for advancing preclinical and clinical workflows.

• CHIR-99021 (CT99021): Precision GSK-3 Inhibition in Organoid

  2026-05-05

  CHIR-99021 (CT99021) empowers researchers to precisely modulate Wnt/β-catenin and TGF-β/Nodal signaling pathways, revolutionizing stem cell pluripotency maintenance, differentiation, and advanced organoid workflows. This article details experimental best practices, troubleshooting strategies, and applied innovations—anchored in recent breakthroughs in suspension-cultured human intestinal organoids.

• HR Repair Gene Profiling Predicts Olaparib Response in Mesot

  2026-05-05

  Borchert et al. (2019) systematically profiled homologous recombination repair (HRR) pathway genes in malignant pleural mesothelioma (MPM), revealing that BRCAness phenotypes—especially BAP1 mutations—predict susceptibility to PARP inhibition by olaparib. Their findings highlight gene-expression signatures that distinguish patient subgroups likely to benefit from targeted combination therapies, informing both prognostic assessment and therapeutic strategy.

• Clozapine in Translational Schizophrenia Research: Bench to

  2026-05-04

  This thought-leadership article illuminates the unique mechanistic actions of Clozapine in schizophrenia models, with a focus on ERK1/2 and EGF receptor–mediated signaling in the prefrontal cortex. Integrating recent advances in noninvasive brain stimulation, it offers strategic guidance for translational researchers navigating assay optimization, safety considerations, and emerging molecular targets. The article is grounded in current evidence and differentiates itself by bridging molecular pharmacology with protocol-driven insights and the latest neurotechnological interventions.

• Selective Recovery of Moraxella Species: MSVA Agar Innovatio

  2026-05-04

  This study introduces Moraxella Selective Vancomycin Agar (MSVA), a medium that markedly improves the isolation of diverse Moraxella species from bovine specimens by suppressing contaminant growth. The findings enable greater specificity in pathogen detection, supporting research into infectious bovine keratoconjunctivitis (IBK) and bacterial diversity in cattle.

• Phosphatase Inhibitor Cocktail 1 (100X): Precision in Phosph

  2026-05-03

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) is a targeted alkaline phosphatase inhibitor enabling reliable protein phosphorylation preservation. Its validated formulation supports high-fidelity phosphoproteomic analysis and robust performance in Western blot and cell signaling assays.

• ampC and ampD Mutations Drive Adaptive Ceftolozane-Tazobacta

  2026-05-02

  This study delineates how specific ampC and ampD mutations in Pseudomonas aeruginosa induce resistance to ceftolozane-tazobactam and alter susceptibility to imipenem. Using semi-mechanistic PKPD modeling, the authors offer a quantitative framework to separate initial and adaptive resistance mechanisms, providing a foundation for more precise antibiotic resistance assays and therapy optimization.

• Applied Workflows with Ampicillin Sodium: Boosting Antibacte

  2026-05-02

  Ampicillin sodium, a benchmark β-lactam antibiotic, sets the standard for robust antibacterial activity assays and bacterial cell wall biosynthesis inhibition studies. This guide delivers actionable experimental workflows, troubleshooting strategies, and key comparative insights—anchored in leading literature and APExBIO’s quality assurance.

• Cholecystokinin Octapeptide Ammonium: Applied Protocols & In

  2026-05-01

  Cholecystokinin octapeptide ammonium (CCK-8 ammonium) unlocks advanced neurobehavioral, immunomodulatory, and cardiac research applications through its receptor-specific actions and high experimental reproducibility. This guide translates bench-side findings—including those on opioid antagonism and ANP induction—into stepwise, evidence-based workflows and troubleshooting strategies for maximizing APExBIO’s CCK-8 ammonium in translational studies.

• Sulfo-Cy3 Azide: Precision Bioconjugation in Neurodevelopmen

  2026-04-30

  Explore how Sulfo-Cy3 azide, a leading bioconjugation reagent, enables reproducible and photostable fluorescent labeling in advanced Click Chemistry assays. This article reveals new insights into protocol optimization and neurodevelopmental imaging.

453 records 19/31 page Previous Next First page 上5页 1617181920 下5页 Last page